FEMY Femasys Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: FEMY

Price (delayed)

$2.58

Market cap

$21.61M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.53

Enterprise value

$24.95M

?
Relative Growth: Rel. Growth: 61
Relative Strength: Rel. Strength: 3
Relative Valuation: Rel. Valuation: 14
Relative Profitability: Rel. Profitability: 25

Femasys is a biomedical company focused on meeting significant unmet needs for women worldwide by developing two lead revolutionary product candidates in late-stage clinical development for reproductive health in addition ...

Highlights
The EPS has surged by 79% year-on-year and by 34% since the previous quarter
FEMY's net income is up by 42% YoY
The equity has surged by 167% year-on-year but it has declined by 45% since the previous quarter
FEMY's quick ratio has dropped by 77% since the previous quarter but it is up by 28% year-on-year
FEMY's gross margin is down by 6% year-on-year
Sector: Healthcare
Industry: Medical Instruments & Supplies
Peers: OFIX

Key stats

What are the main financial stats of FEMY

FEMY stock price

How has the Femasys stock price performed over time
Intraday
0.78%
1 week
1.57%
1 month
-12.84%
1 year
-62.55%
YTD
-77.6%
QTD
-38.28%

Financial performance

How have Femasys's revenue and profit performed over time
Revenue
$2.3M
Gross profit
$1.4M
Operating income
-$17.57M
Net income
-$12.29M
Gross margin
60.9%
Net margin
-534.3%
Femasys's net margin has soared by 52% YoY but it has decreased by 2.4% from the previous quarter
FEMY's net income is up by 42% YoY
The company's operating margin rose by 25% YoY but it fell by 11% QoQ
Femasys's revenue has increased by 22% YoY but it has decreased by 3.3% QoQ

Price vs fundamentals

How does FEMY's price correlate with its fundamentals

Growth

What is Femasys's growth rate over time

Valuation

What is Femasys stock price valuation
P/E
N/A
P/B
1.93
P/S
3.77
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
10.85
The EPS has surged by 79% year-on-year and by 34% since the previous quarter
The equity has surged by 167% year-on-year but it has declined by 45% since the previous quarter
FEMY's price to book (P/B) is 54% less than its 5-year quarterly average of 4.2 and 48% less than its last 4 quarters average of 3.7
The price to sales (P/S) is 81% less than the 5-year quarterly average of 19.5 and 57% less than the last 4 quarters average of 8.7
Femasys's revenue has increased by 22% YoY but it has decreased by 3.3% QoQ

Efficiency

How efficient is Femasys business performance
The ROE has soared by 68% YoY and by 12% from the previous quarter
Femasys's return on invested capital has surged by 57% YoY and by 8% QoQ
The return on sales has surged by 53% year-on-year but it has declined by 5% since the previous quarter
The return on assets has surged by 51% year-on-year

Dividends

What is FEMY's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for FEMY.

Financial health

How did Femasys financials performed over time
The total assets is 49% greater than the total liabilities
FEMY's current ratio has soared by 140% YoY but it is down by 45% QoQ
FEMY's quick ratio has dropped by 77% since the previous quarter but it is up by 28% year-on-year
Femasys's debt is 19% more than its equity
The equity has surged by 167% year-on-year but it has declined by 45% since the previous quarter
FEMY's debt to equity has surged by 83% since the previous quarter but it has dropped by 77% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.